Emily Turner

Emily Turner, PhD, currently serves as Senior Manager of Medical Writing at Xenon Pharmaceuticals Inc. since July 2022, previously holding the position of Manager of Medical Writing. Prior to this role, Emily was affiliated with the Critical Path Institute (C-Path) from July 2019 to June 2022, where responsibilities included serving as Executive Director of the Huntington's Disease Regulatory Science Consortium (HD-RSC) and Senior Scientific Director. Earlier experiences include a Postdoctoral Fellowship at the ASU Biodesign Institute within the Arizona Alzheimer's Consortium (June 2017 - June 2019) and research roles at Northwestern University (December 2010 - June 2012) in The Anxiety Lab and Visual Cognition Lab. Education highlights include a PhD in Psychological Sciences (Neuroscience) from Vanderbilt University (2012-2017) and a BA in Psychology and Art History from Northwestern University (2008-2012).